Tianjin Medical Journal ›› 2022, Vol. 50 ›› Issue (10): 1083-1087.doi: 10.11958/20220196
• Clinical Research • Previous Articles Next Articles
FENG Liting(), WANG Xing, LI Li(
), WU Qi
Received:
2022-02-10
Revised:
2022-03-29
Published:
2022-10-15
Online:
2022-10-20
Contact:
LI Li
E-mail:flt8705@163.com;lily20060718@163.com
FENG Liting, WANG Xing, LI Li, WU Qi. Clinical characteristics of persons infected with imported SARS-CoV-2 Omicron variant in Tianjin[J]. Tianjin Medical Journal, 2022, 50(10): 1083-1087.
CLC Number:
组别 | 年龄(岁) | 男性 | 疫苗 接种史 | 吸烟史 | 咳嗽 | 咽干 咽痛 | 发热 | 乏力 | 鼻塞 流涕 | 头痛 | 肌肉 酸痛 | 嗅觉 减退 | 腹泻 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
无肺炎表现组 | 29.5(24.0,40.5) | 16(61.5) | 23(88.5) | 7(26.9) | 14(53.8) | 10(38.5) | 9(34.6) | 3(11.5) | 6(23.1) | 4(15.4) | 1(3.8) | 0 | 0 |
有肺炎表现组 | 35.5(24.0,53.0) | 21(80.8) | 24(92.3) | 10(38.5) | 12(46.2) | 15(57.7) | 14(53.8) | 8(30.8) | 5(19.2) | 1(3.8) | 1(3.8) | 2(7.7) | 1(3.8) |
Z、χ2或P | 2.392* | 2.342 | 1.000▲ | 0.787 | 0.308 | 1.926 | 1.949 | 2.882 | 0.115 | 0.350▲ | 0.000 | 0.490▲ | 1.000▲ |
Tab. 1 Comparison of general data between the two groups
组别 | 年龄(岁) | 男性 | 疫苗 接种史 | 吸烟史 | 咳嗽 | 咽干 咽痛 | 发热 | 乏力 | 鼻塞 流涕 | 头痛 | 肌肉 酸痛 | 嗅觉 减退 | 腹泻 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
无肺炎表现组 | 29.5(24.0,40.5) | 16(61.5) | 23(88.5) | 7(26.9) | 14(53.8) | 10(38.5) | 9(34.6) | 3(11.5) | 6(23.1) | 4(15.4) | 1(3.8) | 0 | 0 |
有肺炎表现组 | 35.5(24.0,53.0) | 21(80.8) | 24(92.3) | 10(38.5) | 12(46.2) | 15(57.7) | 14(53.8) | 8(30.8) | 5(19.2) | 1(3.8) | 1(3.8) | 2(7.7) | 1(3.8) |
Z、χ2或P | 2.392* | 2.342 | 1.000▲ | 0.787 | 0.308 | 1.926 | 1.949 | 2.882 | 0.115 | 0.350▲ | 0.000 | 0.490▲ | 1.000▲ |
组别 | CRP(mg/L) | PCT(μg/L) | IL-6(ng/L) | D-二聚体(mg/L) | WBC(×109/L) | |||||
---|---|---|---|---|---|---|---|---|---|---|
无肺炎表现组 | 6.05(2.62,13.88) | 0.11(0.09,0.13) | 3.9(2.7,6.9) | 0.25(0.14,0.52) | 5.62±2.12 | |||||
有肺炎表现组 | 3.98(1.80,12.83) | 0.11(0.08,0.13) | 5.3(2.9,10.3) | 0.22(0.14,0.33) | 5.60±1.46 | |||||
Z或t | 0.467 | 0.097 | 1.143 | 0.348 | 0.058 | |||||
组别 | LYM(×109/L) | T细胞(个/μL) | CD4+细胞(个/μL) | CD8+细胞(个/μL) | CD4+/CD8+ | |||||
无肺炎表现组 | 1.54(1.08,1.78) | 1 222.84(891.90,1 423.21) | 626.48(356.67,865.81) | 430.63(212.10,544.94) | 1.68(1.05,2.43) | |||||
有肺炎表现组 | 1.70(1.09,2.04) | 1 241.83(887.44,1 610.06) | 710.97(360.28,1 004.81) | 464.83(374.89,545.22) | 1.58(1.11,2.02) | |||||
Z或t | 0.681 | 0.742 | 0.835 | 0.959 | 0.186 |
Tab. 2 Comparison of laboratory indicators between the two groups
组别 | CRP(mg/L) | PCT(μg/L) | IL-6(ng/L) | D-二聚体(mg/L) | WBC(×109/L) | |||||
---|---|---|---|---|---|---|---|---|---|---|
无肺炎表现组 | 6.05(2.62,13.88) | 0.11(0.09,0.13) | 3.9(2.7,6.9) | 0.25(0.14,0.52) | 5.62±2.12 | |||||
有肺炎表现组 | 3.98(1.80,12.83) | 0.11(0.08,0.13) | 5.3(2.9,10.3) | 0.22(0.14,0.33) | 5.60±1.46 | |||||
Z或t | 0.467 | 0.097 | 1.143 | 0.348 | 0.058 | |||||
组别 | LYM(×109/L) | T细胞(个/μL) | CD4+细胞(个/μL) | CD8+细胞(个/μL) | CD4+/CD8+ | |||||
无肺炎表现组 | 1.54(1.08,1.78) | 1 222.84(891.90,1 423.21) | 626.48(356.67,865.81) | 430.63(212.10,544.94) | 1.68(1.05,2.43) | |||||
有肺炎表现组 | 1.70(1.09,2.04) | 1 241.83(887.44,1 610.06) | 710.97(360.28,1 004.81) | 464.83(374.89,545.22) | 1.58(1.11,2.02) | |||||
Z或t | 0.681 | 0.742 | 0.835 | 0.959 | 0.186 |
组别 | BMI(kg/m2) | CRP(mg/L) | PCT(μg/L) | IL-6(ng/L) | D-二聚体(mg/L) | WBC(×109/L) | ||||
---|---|---|---|---|---|---|---|---|---|---|
无进展组 | 25.8±5.5 | 3.02(1.28,7.49) | 0.11(0.08,0.14) | 5.3(1.9,9.2) | 0.20(0.10,0.24) | 5.46±1.49 | ||||
进展组 | 23.8±4.3 | 8.05(2.62,17.02) | 0.11(0.08,0.13) | 6.5(2.7,11.7) | 0.26(0.16,0.48) | 5.76±1.48 | ||||
t或Z | 1.042 | 1.800 | 0.522 | 0.928 | 1.133 | 0.501 | ||||
组别 | LYM(个/μL) | T细胞(个/μL) | CD4+细胞(个/μL) | |||||||
无进展组 | 1 695.25(1 333.10,2 671.74) | 1 241.83(1 053.47,2 244.44) | 743.55(553.84,1 181.29) | |||||||
进展组 | 1 421.17(1 007.55,1 947.40) | 1 088.28(788.41,1 442.69) | 535.53(309.83,927.19) | |||||||
t或Z | 0.956 | 1.121 | 1.451 |
Tab. 3 Comparison of the laboratory indicators between the two subgroups
组别 | BMI(kg/m2) | CRP(mg/L) | PCT(μg/L) | IL-6(ng/L) | D-二聚体(mg/L) | WBC(×109/L) | ||||
---|---|---|---|---|---|---|---|---|---|---|
无进展组 | 25.8±5.5 | 3.02(1.28,7.49) | 0.11(0.08,0.14) | 5.3(1.9,9.2) | 0.20(0.10,0.24) | 5.46±1.49 | ||||
进展组 | 23.8±4.3 | 8.05(2.62,17.02) | 0.11(0.08,0.13) | 6.5(2.7,11.7) | 0.26(0.16,0.48) | 5.76±1.48 | ||||
t或Z | 1.042 | 1.800 | 0.522 | 0.928 | 1.133 | 0.501 | ||||
组别 | LYM(个/μL) | T细胞(个/μL) | CD4+细胞(个/μL) | |||||||
无进展组 | 1 695.25(1 333.10,2 671.74) | 1 241.83(1 053.47,2 244.44) | 743.55(553.84,1 181.29) | |||||||
进展组 | 1 421.17(1 007.55,1 947.40) | 1 088.28(788.41,1 442.69) | 535.53(309.83,927.19) | |||||||
t或Z | 0.956 | 1.121 | 1.451 |
组别 | GGO | 实变影 | 条索影 | 小叶核心结节 | 支气管扩张 | 受累肺叶数 | 胸膜增厚 | 胸腔积液 | 心包增厚 | 心包积液 |
---|---|---|---|---|---|---|---|---|---|---|
无进展组 | 11(84.6) | 3(23.1) | 3(23.1) | 0(0.0) | 0(0.0) | 1(1,1) | 7(53.8) | 4(30.8) | 1(7.7) | 0(0.0) |
进展组 | 12(92.3) | 10(76.9) | 3(23.1) | 1(7.7) | 1(7.7) | 2(1,4) | 1(7.7) | 3(23.1) | 2(15.4) | 1(7.7) |
P或Z | 1.000▲ | 0.017▲ | 1.000▲ | 1.000▲ | 1.000▲ | 2.467* | 0.030▲ | 1.000▲ | 1.000▲ | 1.000▲ |
Tab. 4 CT characteristics within 1 week after admission of the two subgroups
组别 | GGO | 实变影 | 条索影 | 小叶核心结节 | 支气管扩张 | 受累肺叶数 | 胸膜增厚 | 胸腔积液 | 心包增厚 | 心包积液 |
---|---|---|---|---|---|---|---|---|---|---|
无进展组 | 11(84.6) | 3(23.1) | 3(23.1) | 0(0.0) | 0(0.0) | 1(1,1) | 7(53.8) | 4(30.8) | 1(7.7) | 0(0.0) |
进展组 | 12(92.3) | 10(76.9) | 3(23.1) | 1(7.7) | 1(7.7) | 2(1,4) | 1(7.7) | 3(23.1) | 2(15.4) | 1(7.7) |
P或Z | 1.000▲ | 0.017▲ | 1.000▲ | 1.000▲ | 1.000▲ | 2.467* | 0.030▲ | 1.000▲ | 1.000▲ | 1.000▲ |
[1] | MARUKI T, IWAMOTO N, KANDA K, et al. Two cases of breakthrough severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infections caused by the Omicron variant(B.1.1.529 lineage)in international travelers to Japan[J]. Clin Infect Dis, 2022, 75(1):e354-e356. doi: 10.1093/cid/ciab1072. |
[2] | MOHAPATRA R K, SARANGI A K, KANDI V, et al. Omicron(B.1.1.529 variant of SARS-CoV-2);an emerging threat:Current global scenario[J]. J Med Virol, 2022, 94(5):1780-1783. doi: 10.1002/jmv.27561. |
[3] | CASTRO-CASTRO M J, GARCIA-TEJADA L, ARBIOL-ROCA A, et al. Dynamic profiles and predictive values of some biochemical and haematological quantities in COVID-19 inpatients[J]. Biochem Med (Zagreb),2022, 32(1):010706. doi: 10.11613/BM.2022.010706. |
[4] | YANG Y, HU X, XIONG L, et al. Clinical characteristics of hospitalized mild/moderate COVID-19 patients with a prolonged negative conversion time of SARS-CoV-2 nucleic acid detection[J]. BMC Infect Dis, 2021, 21(1):141. doi: 10.1186/s12879-021-05851-z. |
[5] | FUKUI S, INUI A, SAITA M, et al. Comparison of the clinical parameters of patients with COVID-19 and influenza using blood test data:a retrospective cross-sectional survey[J]. J Int Med Res, 2022, 50(2):3000605221083751. doi: 10.1177/03000605221083751. |
[6] | 于洪志, 邵红霞, 邢志珩, 等. 天津地区新型冠状病毒肺炎患者临床特征分析[J]. 天津医药, 2020, 48(7):577-582. |
YU H Z, SHAO H X, XING Z H, et al. Analysis of clinical characteristics of patients with COVID-19 in Tianjin[J]. Tianjin Med J, 2020, 48(7):577-582. doi: 10.11958/20201093. | |
[7] | GLOCKER M O, OPUNI K F M, THIESEN H J. From free binding energy calculations of SARS-CoV-2-receptor interactions to cellular immune responses[J]. Medicina (Kaunas), 2022, 58(2):226. doi: 10.3390/medicina58020226. |
[8] | SINGHAL T. The emergence of Omicron:Challenging times are here again![J]. Indian J Pediatr, 2022, 89(5):490-496. doi: 10.1007/s12098-022-04077-4. |
[9] | KIM M K, LEE B, CHOI Y Y, et al. Clinical characteristics of 40 patients infected with the SARS-CoV-2 omicron variant in Korea[J]. J Korean Med Sci, 2022, 37(3):e31. doi: 10.3346/jkms.2022.37.e31. |
[10] | SHUAI H, CHAN J F, HU B, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron[J]. Nature, 2022, 603(7902):693-699. doi: 10.1038/s41586-022-04442-5. |
[11] | MENG B, ABDULLAHI A, FERREIRA I A T M, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts tropism and fusogenicity[J]. Nature, 2022, 603(7902):706-714. doi: 10.1038/s41586-022-04474-x. |
[12] | WOLTER N, JASSAT W, WALAZA S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa:a data linkage study[J]. Lancet, 2022, 399(10323):437-446. doi: 10.1016/S0140-6736(22)00017-4. |
[13] | FEIKIN D R, HIGDON M M, ABU-RADDAD L J, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease:results of a systematic review and meta-regression[J]. Lancet, 2022, 399(10328):924-944. doi: 10.1016/S0140-6736(22)00152-0. |
[14] | MODES M E, DIRECTO M P, MELGAR M, et al. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2(Delta)and B.1.1.529(Omicron)variant predominance - one hospital,California,July 15-September 23,2021,and December 21,2021-January 27,2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(6):217-223. doi: 10.15585/mmwr.mm7106e2. |
[15] | FANTINI J, YAHI N, COLSON P, et al. The puzzling mutational landscape of the SARS-2-variant Omicron[J]. J Med Virol, 2022, 94(5):2019-2025. doi: 10.1002/jmv.27577. |
[1] | QI Fumin, SU Rui, HAO Jian, SU Li, FAN Qian, LI Xin, WEI Wei. Study on the protective effect of vaccine in patients with microscopic polyangiitis-interstitial lung disease complicated with COVID-19 infection [J]. Tianjin Medical Journal, 2024, 52(7): 683-686. |
[2] | LYU Mengna, LI Jianbin, WU Rui. Early predictors of the severity of COVID-19 in patients with autoinflammatory diseases [J]. Tianjin Medical Journal, 2024, 52(5): 528-531. |
[3] | FENG Liting, LI Li, XIE Xin, WANG Xing. Analysis of influencing factors of chronic obstructive pulmonary disease in permanent residents in some area of Tianjin [J]. Tianjin Medical Journal, 2024, 52(4): 427-431. |
[4] | NIJAT Alim, MA Shifeng, XAMSIYA Alim, ZHANG Jing, ZHENG Rongxiu. Analysis of clinical characteristics and risk factors for diabetes mellitus complicated with urinary tract infection in children [J]. Tianjin Medical Journal, 2024, 52(10): 1051-1055. |
[5] | GU Songtao, JIA Wei, LI Yuechuan, ZHANG Dongrui, ZHANG Yating, GAO Shulian, LI Na. Clinical characteristics of COVID-19 complicated with pulmonary thromboembolism [J]. Tianjin Medical Journal, 2023, 51(8): 873-877. |
[6] | LIU Yufei, ZHU Ju, LIU Na, REN Yanping, SUN Xiaohui, TIAN Li, ZHANG Zhecheng. Clinical characteristics of amyotrophic lateral sclerosis patients [J]. Tianjin Medical Journal, 2023, 51(7): 681-686. |
[7] | ZHONG Muxian, XIE Xinrong. Analysis of clinical characteristics of diabetic ketoacidosis complicated with coronavirus disease 2019 [J]. Tianjin Medical Journal, 2023, 51(12): 1378-1381. |
[8] | CUI Yaqiong, LIU Wei. COVID-19 infection-associated multisystem inflammatory syndrome and cytokine storms in children [J]. Tianjin Medical Journal, 2022, 50(12): 1340-1344. |
[9] | WANG Yuliang, LONG Yiyin, CHEN Xiaobo. Genetic and pathogenic characteristics of SARS-CoV-2 variants [J]. Tianjin Medical Journal, 2022, 50(10): 1103-1109. |
[10] | GUO Jing, LI Li, WU Qian, LI Hong-wei, SHI Li-xia, WU Qi. The effect of the systemic immune-inflammation index on conversion time of virus nucleic acid turning negative in COVID-19 patients [J]. Tianjin Medical Journal, 2021, 49(11): 1188-1192. |
[11] |
ZHAO Lei , XUE Jian , WANG Yu-ling△, DAI Er-hei , XU Zun-gui , LI Ya-nan , DUN Zi-qian , GAO Hui-xia , RONG Yan-xiao , CHEN Can.
The clinical feature and imaging analysis of patients with new coronavirus infection in Shijiazhuang
[J]. Tianjin Medical Journal, 2020, 48(7): 588-591.
|
[12] | WANG Xiao-wu, ZHU Yi-lang, LI Tuan-tuan, GAO Yong△. Evaluation of SARS-COV-2 nucleic acid in convalescent anal swabs of patients with coronavirus disease 2019 [J]. Tianjin Medical Journal, 2020, 48(7): 592-595. |
[13] | PENG Ming, LI Yu-kai, WANG Lan, XIAO Jie, CHENG Zhong△. The influence of coronary heart disease on the development and prognosis of COVID-19 patients [J]. Tianjin Medical Journal, 2020, 48(7): 599-602. |
[14] | YU Hong-zhi , SHAO Hong-xia , XING Zhi-heng , QIN Zhong-hua , FU Sha-sha , HU Song , WU Qi△. Analysis of clinical characteristics of patients with COVID-19 in Tianjin [J]. Tianjin Medical Journal, 2020, 48(7): 577-582. |
[15] | YU Hong-zhi, XU Lei, CONG Hong-liang, WU Qi△. Discussion on the treatment of COVID-19 in Tianjin [J]. Tianjin Medical Journal, 2020, 48(6): 479-482. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||